Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 29;27(6):1026-1036.
doi: 10.5603/RPOR.a2022.0113. eCollection 2022.

Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study

Soniya Mohammed  1 , M Dinesan  1 , T Ajayakumar  1
Affiliations

Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study

Soniya Mohammed et al. Rep Pract Oncol Radiother. .

Abstract

Background: Glioblastoma multiforme (GBM) is the most common and aggressive primary intracranial tumor. Despite modern therapies, it is still fatal with tremendously poor prognosis with a median survival of 14 months. Even though mean survival and progression-free survival (PFS) are considered as primary response measure, it is important to assess the effects of therapies on disease burden and health-related quality of life (HRQoL). Changes in quality of life (QoL) indicates the impact of cytotoxic therapy and may aid in defining response in the absence of quantifiable endpoints like tumor regression. The objective was to assess 2-year survival and quality of life in GBM patients who underwent primary surgery followed by chemo-radiotherapy and 6-month adjuvant chemotherapy with temozolomide.

Materials and methods: Single-institution retrospective study of 60 patients of GBM from 2015 to 2017. Data regarding patient factors, disease factors, and treatment factors were collected and survival was calculated.

Results: 60 patients with GBM were analyzed, male to female ratio was 1.6:1. Patients most commonly presented with headache. Most common tumour site is the frontal lobe. The median overall survival (OS) was 10 months. The 1-year and 2-year survival rates were 30% and 6.7%, respectively. Compared to before surgery patients have showed improved emotional, social and role functioning in Post radiotherapy period. There was a decrease in symptoms like pain, headache and seizures.

Conclusions: OS and QoL in GBM patients remains poor despite constant research and studies. Maximum safe resection followed by adjuvant temozolomide has shown improvement in OS. Post-surgery and adjuvant radiotherapy patients have shown a decrease in symptoms and better QoL.

Keywords: glioblastoma multiforme; overall survival; quality of life; temozolomide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Eastern Cooperative Oncology Group (ECOG) performance score
Figure 2
Figure 2
Overall survival (OS)
Figure 3
Figure 3
Survival analysis with adjuvant temozolomide (TMZ) vs. no adjuvant temozolomide
Figure 4
Figure 4
Improvement in dimensions of quality of life — European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire (EORTC QLQ-C30). In general quality of life assessment showed significant improvement in emotional, social and role functioning along with overall global health status in the post-radiation period and a decrease in symptoms like fatigue and pain. The symptoms like nausea and vomiting showed an increased incidence
Figure 5
Figure 5
Improvement in dimensions of quality of life—European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire brain cancer module (EORTC QLQ-BN20). Post radiation patients have decreased incidence of symptoms like headache and seizures. There is an improvement in motor functioning, weakness of leg and communication deficit. Patients are also concerned about post-radiation hair fall
See this image and copyright information in PMC

References

    1. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16(7):896–913. doi: 10.1093/neuonc/nou087. - DOI - PMC - PubMed
    1. Zhang YH, Li Z, Zeng T, et al. Distinguishing Glioblastoma Subtypes by Methylation Signatures. Front Genet. 2020;11:604336. doi: 10.3389/fgene.2020.604336. - DOI - PMC - PubMed
    1. Dubrow R, Darefsky AS. Demographic variation in incidence of adult glioma by subtype, United States, 1992–2007. BMC Cancer. 2011;11:325. doi: 10.1186/1471-2407-11-325. - DOI - PMC - PubMed
    1. Krex D, Klink B, Hartmann C, et al. German Glioma Network. Long-term survival with glioblastoma multiforme. Brain. 2007;130(Pt 10):2596–2606. doi: 10.1093/brain/awm204. - DOI - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed

LinkOut - more resources